NCT01209104View on ClinicalTrials.gov

Pharmacokinetics and Safety of GSK1325756 in Elderly Subjects and Adult Subjects of in the Fed and Fasted States and in the Presence of a Proton Pump Inhibitors

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 14, 2010

Primary Completion Date

May 24, 2010

Study Completion Date

May 24, 2010

Conditions
Nutritional Status
Interventions
DRUG

GSK1325756

100mg of a single oral dose of GSK1325756 administered as 2 x 50mg tablets

DRUG

GSK1325756

100mg of a single oral dose of GSK1325756 administered as 2 x 50mg tablets

Trial Locations (1)

55404

GSK Investigational Site, Minneapolis

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01209104 - Pharmacokinetics and Safety of GSK1325756 in Elderly Subjects and Adult Subjects of in the Fed and Fasted States and in the Presence of a Proton Pump Inhibitors | Biotech Hunter | Biotech Hunter